BioNTech Partner's Drug Candidate Faces FDA Clinical Hold

TL;DR

FDA puts BioNTech partner's cancer drug ONC-390 on clinical hold, halting trials.

AI Summary

BioNTech SE announced on October 18, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investigational new drug (IND) application for ONC-390, a novel antibody targeting the C4 complement protein. The FDA has placed a clinical hold on the IND application, meaning further clinical trials for ONC-390 cannot proceed until specific issues are resolved.

Why It Matters

This FDA clinical hold on ONC-390 could delay BioNTech's potential revenue from this drug candidate and impacts the development timeline for a new cancer therapy.

Risk Assessment

Risk Level: medium — A clinical hold introduces significant uncertainty and delays for a drug candidate, potentially impacting future revenue and market entry.

Key Players & Entities

• BioNTech SE (company) — Registrant and partner's collaborator
• OncoC4, Inc. (company) — BioNTech's partner
• U.S. Food and Drug Administration (FDA) (company) — Regulator that placed the clinical hold
• ONC-390 (drug_candidate) — Investigational drug targeting C4 complement protein
• October 18, 2024 (date) — Date of the announcement

FAQ

Filing Documents

• form6-kbnt31618oct2024.htm (6-K) — 18KB
• 0001776985-24-000085.txt ( ) — 19KB

Forward-Looking Statements

Forward-Looking Statements This statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the next steps in the PRESERVE-003 trial and other clinical trials of BNT316ONC-392, the potential that BNT316ONC-392 may help to preserve T cell activity and enhance anti-tumor activity, and the potential efficacy and safety of BNT316ONC-392. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this statement are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Quarterly Report on Form 6-K for the period ended June 30, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at httpswww.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this statement in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by

View Full Filing

View this 6-K filing on SEC EDGAR